Literature DB >> 2369809

Transintestinal elimination of ciprofloxacin.

R W Rohwedder1, T Bergan, S B Thorsteinsson, H Scholl.   

Abstract

This study identified the routes of elimination of ciprofloxacin in two groups of five subjects each: one of healthy volunteers; the other of patients with severe renal failure having mean creatinine clearance of 12 ml/min (range, 8-16 ml/min). Each subject received one dose of 200 mg ciprofloxacin infused intravenously (IV) over 30 min. In an effort to recover the total drug administered, all urine and feces were collected for 7 days following dosing. Blood samples were drawn at set intervals. Serum, urine, and feces were assayed for ciprofloxacin and metabolites by high-pressure liquid chromatography. The ciprofloxacin elimination half-life was 3.9 +/- 0.4 hr in the healthy volunteers and 11.2 +/- 2.5 hr in the patients with severe renal failure. The total 7-day recovery of ciprofloxacin and its metabolites in urine and feces ranged from 74.0% to 114.7% of the dose (mean, 96.3 +/- 14.1%) in normal subjects and from 48.5% to 109.1% (mean, 88.1 +/- 20.9%) in patients. The dose of ciprofloxacin recovered in urine was 65.3 +/- 10.7% in healthy subjects and 19.0 +/- 15.9% in impaired patients (reduction factor, 3.4). In contrast, the dose recovered in feces was 11.4 +/- 2.6% in the group of normal subjects and 37.2 +/- 12.5% in the group of patients with impaired renal function in a 3.3-fold increase.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2369809     DOI: 10.1016/0732-8893(90)90095-d

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  8 in total

1.  Intestinal ciprofloxacin efflux: the role of breast cancer resistance protein (ABCG2).

Authors:  I S Haslam; J A Wright; D A O'Reilly; D J Sherlock; T Coleman; N L Simmons
Journal:  Drug Metab Dispos       Date:  2011-09-19       Impact factor: 3.922

2.  Influence of intravenously administered ciprofloxacin on aerobic intestinal microflora and fecal drug levels when administered simultaneously with sucralfate.

Authors:  W A Krueger; G Ruckdeschel; K Unertl
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Ciprofloxacin decreases the rate of ethanol elimination in humans.

Authors:  J Tillonen; N Homann; M Rautio; H Jousimies-Somer; M Salaspuro
Journal:  Gut       Date:  1999-03       Impact factor: 23.059

4.  The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study.

Authors:  Kiran Shekar; John F Fraser; Fabio Silvio Taccone; Susan Welch; Steven C Wallis; Daniel V Mullany; Jeffrey Lipman; Jason A Roberts
Journal:  Crit Care       Date:  2014-12-12       Impact factor: 9.097

Review 5.  A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life.

Authors:  Jan-Frederik Schlender; Donato Teutonico; Katrin Coboeken; Katrin Schnizler; Thomas Eissing; Stefan Willmann; Ulrich Jaehde; Heino Stass
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

6.  Application of a Physiologically Based Pharmacokinetic Model to Study Theophylline Metabolism and Its Interactions With Ciprofloxacin and Caffeine.

Authors:  A Navid; D M Ng; S E Wong; F C Lightstone
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-02-16

7.  Treatment of severe pneumonia by hinokitiol in a murine antimicrobial-resistant pneumococcal pneumonia model.

Authors:  Toshihito Isono; Hisanori Domon; Kosuke Nagai; Tomoki Maekawa; Hikaru Tamura; Takumi Hiyoshi; Katsunori Yanagihara; Eiji Kunitomo; Shoji Takenaka; Yuichiro Noiri; Yutaka Terao
Journal:  PLoS One       Date:  2020-10-15       Impact factor: 3.240

8.  Predictive Performance of Physiology-Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small-Molecule Compounds in Children.

Authors:  Ibrahim Ince; André Dallmann; Sebastian Frechen; Katrin Coboeken; Christoph Niederalt; Thomas Wendl; Michael Block; Michaela Meyer; Thomas Eissing; Rolf Burghaus; Jörg Lippert; Stefan Willmann; Jan-Frederik Schlender
Journal:  J Clin Pharmacol       Date:  2021-06       Impact factor: 3.126

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.